On the public citation graph

Remission of uncontrolled type 2 diabetes mellitus in a patient treated with tumor necrosis factor-inhibitor: A case report

https://doi.org/10.5281/zenodo.3558989
0 signed · 24 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2011.1211openalex-extracted
Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events
inferredcites →https://doi.org/10.1007/s00592-010-0237-xopenalex-extracted
Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice
inferredcites →https://doi.org/10.1007/s40265-014-0258-9openalex-extracted
Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases
inferredcites →https://doi.org/10.1016/j.atherosclerosis.2004.04.031openalex-extracted
Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol
inferredcites →https://doi.org/10.1016/s0140-6736(00)02530-7openalex-extracted
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
inferredcites →https://doi.org/10.1038/ajg.2012.334openalex-extracted
T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH Study
inferredcites →https://doi.org/10.1074/jbc.m104602200openalex-extracted
SOCS-3 Inhibits Insulin Signaling and Is Up-regulated in Response to Tumor Necrosis Factor-α in the Adipose Tissue of Obese Mice
inferredcites →https://doi.org/10.1111/apm.12018openalex-extracted
Increased expression of toll‐like receptor 4 and inflammatory cytokines, interleukin‐6 in particular, in islets from a mouse model of obesity and type 2 diabetes
inferredcites →https://doi.org/10.1111/j.1365-2362.2004.01390.xopenalex-extracted
Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti‐TNF‐α antibody infliximab
inferredcites →https://doi.org/10.1111/j.1463-1326.2012.01585.xopenalex-extracted
Exercise increases skeletal muscle GLUT4 gene expression in patients with type 2 diabetes
inferredcites →https://doi.org/10.1111/j.1464-5491.2011.03324.xopenalex-extracted
Meal‐induced increases in C‐reactive protein, interleukin‐6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes
inferredcites →https://doi.org/10.1111/j.1468-3083.2012.04500.xopenalex-extracted
Re‐evaluation of the risk for major adverse cardiovascular events in patients treated with anti‐IL‐12/23 biological agents for chronic plaque psoriasis: a meta‐analysis of randomized controlled trials
inferredcites →https://doi.org/10.1111/jcpt.12045openalex-extracted
Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis
inferredcites →https://doi.org/10.1126/science.271.5249.665openalex-extracted
IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance
inferredcites →https://doi.org/10.1136/ard.2004.023119openalex-extracted
Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis
inferredcites →https://doi.org/10.1136/ard.2007.072256openalex-extracted
Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus
inferredcites →https://doi.org/10.1161/hypertensionaha.109.143982openalex-extracted
Tumor Necrosis Factor-α Antagonists Improve Aortic Stiffness in Patients With Inflammatory Arthropathies
inferredcites →https://doi.org/10.1186/1752-1947-6-5openalex-extracted
Development of low blood glucose readings in nine non-diabetic patients treated with tumor necrosis factor-alpha inhibitors: a case series
inferredcites →https://doi.org/10.1210/en.2007-1045openalex-extracted
The Proinflammatory Cytokine Tumor Necrosis Factor-α Increases the Amount of Glucose Transporter-4 at the Surface of Muscle Cells Independently of Changes in Interleukin-6
inferredcites →https://doi.org/10.2174/187153009789044347openalex-extracted
TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases
inferredcites →https://doi.org/10.2337/dc09-0054openalex-extracted
Etanercept Treatment in Children With New-Onset Type 1 Diabetes
inferredcites →https://doi.org/10.2353/ajpath.2006.050293openalex-extracted
Severely Impaired Insulin Signaling in Chronic Wounds of Diabetic ob/ob Mice
inferredcites →https://doi.org/10.3349/ymj.2014.55.2.442openalex-extracted
Incidences of Serious Infections and Tuberculosis among Patients Receiving Anti-Tumor Necrosis Factor-α Therapy
inferredcites →https://doi.org/10.3899/jrheum.130543openalex-extracted
Longterm Effect of Delaying Combination Therapy with Tumor Necrosis Factor Inhibitor in Patients with Aggressive Early Rheumatoid Arthritis: 10-year Efficacy and Safety of Adalimumab from the Randomized Controlled PREMIER Trial with Open-label Extension
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.